Navigation Links
Palatin Technologies Announces Third Quarter Fiscal Year 2013 Results and Update on Development of Bremelanotide for Female Sexual Dysfunction
Date:5/14/2013

9,6295,95537,01728,229Interest expense

(1,103)(1,830)(4,746)(6,650)Increase in fair value of warrants

--(7,069,165)-Gain on disposition of supplies and equipment

-1,7004,6204,700Total other income (expense), net

8,5265,825(7,032,274)26,279Loss before income taxes

(4,015,258)(6,020,702)(17,897,334)(13,068,118)Income tax benefit

--1,753,2081,068,233NET LOSS

$
(4,015,258)$
(6,020,702)$
(16,144,126)$
(11,999,885)Basic and diluted net loss per common share

$
(0.04)$
(0.17)$
(0.17)$
(0.34)Weighted average number of common shares

outstanding used in computing basic and diluted net

loss per common share

106,424,44334,900,59194,754,78934,900,591 PALATIN TECHNOLOGIES, INC.and SubsidiaryConsolidated Balance Sheets(unaudited)March 31, 2013June 30, 2012ASSETSCurrent assets:Cash and cash equivalents

$
23,537,053$
3,827,198Short-term investments

5,998,740-Accounts receivable

-27,631Restricted cash

-350,000Prepaid expenses and other current assets

488,185532,010Total current assets

30,023,9784,736,839Property and equipment, net

307,020318,653Other assets

58,337324,992Total assets

$
30,389,335$
5,380,484LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Capital lease obligations

$
23,591$
22,277Accounts payable 

733,443294,894Accrued expenses

1,986,2402,706,496Accrued compensation

-433,333Total current liabilities

2,743,2743,457,000Capital lease obligations 

2,04819,909Deferred rent

44,76472,677Total liabilities

2,790,0863,549,586Stockholders' equity:Preferred stock of $0.01 par value – authorized 10,000,000 shares;Series A Convertible; issued and outstanding 4,697 shares as

of March 31, 2013 and 4,997 as of June 30, 2012 

4750Common stock of
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013
2. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
3. Palatin Technologies To Present At The 25th Annual ROTH Conference
4. Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care Conference
5. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
6. Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
7. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
8. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
10. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
11. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... The empty capsules market is ... population and technological innovations in the empty capsules ... catalysing the growth of the empty capsules market. ... , Scope of Report , The report will ... entrants/smaller firms to gauge the pulse of the ...
(Date:12/19/2014)... Dec. 18, 2014 Relmada Therapeutics, Inc. (OTCQB: ... treatment of chronic pain, announced the results of its ... "This was a transformational year in Relmada,s history and ... our company," said Sergio Traversa , chief executive ... executed on key financial, human resource and clinical development ...
(Date:12/17/2014)... BASKING RIDGE, N.J. (PRWEB) December 17, 2014 ... Ipsen (Euronext: IPN; ADR: IPSEY), ... 120 mg (referred to as Somatuline®) was approved ... for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) ... differentiated, locally advanced or metastatic disease to improve ...
(Date:12/17/2014)... 17, 2014 Audacity, a leading California-based ... member of the Huntsworth Health Group, is proud to ... team. In her role, Gonzales will serve as Senior ... incredibly honored to welcome a talent of Jamie’s caliber ... Gaëtan Fraikin. “She is a proven healthcare innovation leader ...
Breaking Biology Technology:Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
... Farm Aid , the rock concert designed to shed light (and ... past weekend in Chicago. , ,As indicated by the Chicago ... the American farm is not only a center of production. Its ... The Tribune noted that we all lose something each ...
... Madison, Wis. - Undeterred by a small ... people packed the Madison Overture Center Monday night to hear ... Thomson, who used the forum to outline UW's stem cell ... UW-Medical School, made international headlines in 1998 when he announced ...
... GenTel BioSurfaces, Inc. has launched PATHT HTS, a new ... last week at the microarray industry's annual conference, Chips ... very pleased with the performance of PATH protein microarray ... for GenTel BioSurfaces. "PATH HTS was designed ...
Cached Biology Technology:Farm Aid celebrates 20-year journey, heads back to Illinois roots 2Farm Aid celebrates 20-year journey, heads back to Illinois roots 3Thomson gives a blueprint of UW's stem cell research 2
(Date:11/18/2014)... , Nov. 18, 2014  The Secure ... Industry Association today jointly announce the formation of ... release of its Identity and Biometric Entry ... The Framework received official support from BORDERPOL, the ... to improve and provide expertise regarding border security, ...
(Date:11/18/2014)... YORK , Nov. 18, 2014   ... identity authentication solutions, and MorphoTrust USA ... and services, today announced a strategic partnership to ... enterprise, motor vehicle administration (MVA), airport screening and ... in identity-related solutions, MorphoTrust serves consumers through a ...
(Date:11/11/2014)... 2014  Forensicon, Inc., a Chicago ... announce the promotion of Yaniv Schiff from ... In Schiff,s new role as Director, he will lead ... forensics examiners and provide leadership within the company,s digital ... http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined Forensicon in ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... Scientists here have made a major discovery that sheds ... natural killer (NK) cells, powerful but somewhat mysterious components ... line of defense against cancer and infectious diseases. , ... are generated in bone marrow, but Michael Caligiuri, director ...
... vanishingly small realm of molecules and atoms may not ... after all. In fact, research at the National Institute ... version of the optical microscope might be able to ... fraction of the wavelength of visible light. , In ...
... Center scientists have discovered a potential new drug that ... one-third of all cancers. The scientists showed they could ... this new compound, called cysmethynil. , Their finding, reported ... the National Academy of Sciences, is the first step ...
Cached Biology News:Scientists identify new model Of NK cell development 2Scientists identify new model Of NK cell development 3Devising Nano Vision for an Optical Microscope 2Newly Discovered Compound Blocks Known Cancer-Causing Protein 2Newly Discovered Compound Blocks Known Cancer-Causing Protein 3
One-step, microplate or cuvet, turbidometric, linear detection range 0.096 mg/dL to 11.5 mg/dL. Procedure: 5 min....
... sizing single-stranded RNA ranging from 0.5 kb to 10 ... consists of nine bands in even increments (0.5 1 ... to simplify size estimation. The 1.5 kb band is ... and identification of RNA bands on the gel. All ...
Recombinant Mouse Wnt-3a...
Homo sapiens jumping translocation breakpoint...
Biology Products: